BPG is committed to discovery and dissemination of knowledge
Featured Articles
1/11/2022 12:45:02 AM | Browse: 668 | Download: 1127
Publication Name World Journal of Gastrointestinal Oncology
Manuscript ID 66297
Country Greece
ISSN 1948-5204 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Minireviews
Article Title Trimodality treatment in gastric and gastroesophageal junction cancers: Current approach and future perspectives
Manuscript Source Invited Manuscript
All Author List Nikolaos Charalampakis, Sergios Tsakatikas, Dimitrios Schizas, Stylianos Kykalos, Maria Tolia, Rodanthi Fioretzaki, Georgios Papageorgiou, Ioannis Katsaros, Ahmed Adel Fouad Abdelhakeem, Matheus Sewastjanow-Silva, Jane E Rogers and Jaffer A Ajani
Funding Agency and Grant Number
Corresponding Author Nikolaos Charalampakis, MD, PhD, Attending Doctor, Department of Medical Oncology, Metaxa Cancer Hospital of Piraeus, Mpotasi 51, Piraeus 18537, Greece. nick301178@yahoo.com
Key Words Gastric cancer; Gastroesophageal junction cancer; Trimodality treatment; Chemoradiotherapy; Surgery; Immunotherapy
Core Tip Trimodality treatment combining chemotherapy, radiation and surgery is an effective management of locally advanced gastric and gastroesophageal cancers, although the extent of benefit remains to be answered in future clinical trials. Addition of newer therapeutic agents, such as immune checkpoint inhibitors may further enhance the curative potential of this approach.
Publish Date 2022-01-11 00:11
Citation Charalampakis N, Tsakatikas S, Schizas D, Kykalos S, Tolia M, Fioretzaki R, Papageorgiou G, Katsaros I, Abdelhakeem AAF, Sewastjanow-Silva M, Rogers JE, Ajani JA. Trimodality treatment in gastric and gastroesophageal junction cancers: Current approach and future perspectives. World J Gastrointest Oncol 2022; 14(1): 181-202
URL https://www.wjgnet.com/1948-5204/full/v14/i1/181.htm
DOI https://dx.doi.org/10.4251/wjgo.v14.i1.181
Full Article (PDF) WJGO-14-181.pdf
Full Article (Word) WJGO-14-181.docx